Elrexfio™ (elranatamab-bcmm) – New orphan drug approval
August 14, 2023 - Pfizer announced the FDA approval of Elrexfio (elranatamab-bcmm), for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
Top